Bayer Pharma Aktiengesellschaft

Schering Aktiengesellschaft

Lars Wortmann

Philip Lienau

Knut Eis

Gerhard Siemeister

Antje Margret Wengner

Ulrich Klar

Hans Briem

Ulrich Lücking

Hans Schick

Benjamin Bader

Marcus Koppitz

Detlev Sülzle

Georg Kettschau

Julien Lefranc

Dirk Kosemund

Wilhelm Bone

Joanna Grudzinska-Goebel

Dieter Moosmayer

Uwe Eberspächer

Franz Von Nussbaum

Ulf Bömer

Damian O Arnaiz

Andrea Hägebarth

Keith Graham

Florian Puehler

Florian Pühler

Gary Bruce Phillips

Brad Owen Buckman

Joachim Kuhnke

Martina Schäfer

Monica J Kochanny

Shendong Yuan

Volker Schulze

Kirstin Petersen

Olaf Prien

Richard L Feldman

Holger Hess-Stumpp

Peter Esperling

Judi Bryant

Christoph Huwe

Seock-Kyu Khim

Anja Richter

Florian Püehler

Uwe Eberspaecher

Ulf Bomer

Emil Eckle

Ulrich Lucking

Hans (deseased) Schick

Antje-Margret Wengner

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.

2-(morpholin-4-yl)-1,7-naphthyridines

The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines

The present invention relates to substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (1b), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients. 

The present invention relates to substituted thiazolopyrimidine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Substituted thiazolopyrimidines

The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of formula I, below, as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients wherein R, R, R, and Rare defined herein.

Substituted pyrazolopyrimidinylamino-indazoles

The present invention relates to substituted thienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Thienopyrimidines

The present invention relates to substituted pyrrolopyrimidinylamino-benzothiazolone compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors

The present invention relates to substituted benzothienopyrimidine compounds of general formula I: in which R, R, R, R, and Rare as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients. 

Substituted benzothienopyrimidines

The invention relates to thiazolidinones of general formula (I) their production and use as inhibitors of polo-like kinases (Plk) for treating various diseases.

Thiazolidinones, their production and use as pharmaceutical agents

This invention relates to pyrimidine derivatives of general formula (I) as inhibitors of kinases, their production as well as their use as medications for treating various diseases.

Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents

Growing community of inventors

Berlin, Germany

Lars Wortmann